Cardiovascular disease is the leading cause of mortality in women, yet risk is consistently underestimated during the critical window of perimenopause and menopause. Join Midi’s Chief Medical Officer, Kathleen Jordan, MD, and special guest cardiologist Dr. Sirisha Vadali as they discuss a practical, evidence-based framework for identifying and managing cardiovascular risk in menopause, beyond standard lipid panels.

 The session will feature an applied, interactive discussion centered on real-world case studies from Dr. Vadali's practice. Additionally, our experts will also cover the common misconceptions regarding statin use in women and the role of menopause hormone therapy (MHT).

1. Describe the cardiometabolic shifts associated with perimenopause and menopause, and differentiate hormonal from age-related contributors to cardiovascular risk.
   
   
2. Order and interpret advanced lipid and metabolic markers — including ApoB, Lp(a), LDL particle size, hs-CRP, fasting insulin, HbA1c, and CAC scores — to stratify cardiovascular risk in midlife women.
   
   
3. Apply current evidence to guide statin therapy, lifestyle interventions, and menopause hormone therapy decisions in female patients.
   
   
4. Evaluate the cardiovascular outcomes data for GLP-1 receptor agonists and identify appropriate candidates for this emerging therapy in clinical practice.